Chronic corticosterone aggravates behavioral and neuronal symptomatology in a mouse model of alpha-synuclein pathology
Johannes Burtscher,Jean-Christophe Copin,João Rodrigues,Senthil T Kumar,Anass Chiki,Isabelle Guillot de Suduiraut,Carmen Sandi,Hilal A Lashuel,Senthil T. Kumar,Hilal A. Lashuel
DOI: https://doi.org/10.1016/j.neurobiolaging.2019.08.007
IF: 5.133
2019-11-01
Neurobiology of Aging
Abstract:<p>Debilitating, yet under-investigated non-motor symptoms related to mood/emotion, such as depression, are common in Parkinson's disease. Here we explore the role of depression and of the amygdala, a brain region robustly linked to mood/emotion, in synucleinopathy.</p><p>We hypothesized that mood/emotional deficits might accelerate Parkinson's disease-linked symptomatology, including the formation of α-synuclein pathology.</p><p>We combined elevated corticosterone treatment, modelling chronic stress and depression, with a model of seeded α-synuclein pathology in mouse striatum and assessed behavioral parameters with a focus on mood /emotion, and neuropathology.</p><p>We report behavioural resilience against α-synuclein proteinopathy in the absence of additional insults, potentially based on hormesis / conditioning mechanisms. Elevated corticosterone, however, reversed α-synuclein pathology induced behavioral adaptations, and was associated with increased dopaminergic cell loss as well as aggravated α-synuclein pathology in specific brain regions, such as the entorhinal cortex. These findings point to elevated glucocorticoids as a risk factor for Parkinson's disease progression and highlight the potential of glucocorticoid level reducing strategies to slow down disease progression in synucleinopathy.</p>
neurosciences,geriatrics & gerontology,gerontology